Cedrik Britten
Chief Medical Officer Immatics
Cedrik Britten has served as Chief Medical Officer of Immatics since 2020, assuming leadership for the management and global clinical development of our adoptive cell therapy and TCR Bispecifics pipeline from first testing in humans to registration trials, including managing regulatory affairs. Cedrik served as Vice President and Head of the Oncology Cell Therapy Research Unit of GlaxoSmithKline plc from 2015 to 2020, being responsible for building the Oncology Cell Therapy Unit and driving the strategy and establishing the end-to-end capabilities required to research and develop innovative cell therapies in oncology. Prior to that, Cedrik served as Vice President of Research and Development of BioNTech RNA Pharmaceuticals GmbH.
Seminars
- Demonstrating first-generation autologous TCR therapy Anzu-Cel achieving 50-60% durable responses in melanoma
- Advancing second-generation efficacy enhanced PRAME TCRs into ovarian and endometrial cancers and the prospect of tissue agnostic expansion
- Bispecific TCR approaches to maximize clinical impact while addressing development and scalability challenges
- Identifying pivotal learnings that can sharpen development strategies and accelerate stronger clinical outcomes
- Framing actionable insights that translate early proof-of-concept gains into durable, real-world clinical impact
- Exploring critical knowledge gaps and defining high-value priorities that can shape the next-generation of TCR innovations
